World's first lower-carbon asthma inhaler approved by MHRA
Same drug, smaller carbon footprint
On 21 July 2026, the MHRA approved the world's first lower-carbon asthma inhalers (Clenil Modulite 100 mcg and 200 mcg) using next-generation propellant HFA-152a. The medicine and effectiveness remain unchanged. Available in the UK later in 2026.
MHRA approves lower-carbon asthma inhalers; same efficacy, reduced environmental impact.
Product details
- For Clenil Modulite 100 mcg and 200 mcg inhalers
- Active ingredient beclometasone unchanged; same clinical benefit
- Uses next-generation propellant HFA-152a to cut carbon emissions
Safety
- Common side effects: oral thrush, hoarseness, throat irritation
- Report side effects via MHRA Yellow Card scheme
Availability
- Available in the UK later in 2026
- Current versions remain in use until then
Act now
- Ask your pharmacist about the low-carbon version at your next prescription
- Current inhalers remain effective and available
Emergency
If asthma worsens or you have trouble breathing, call 999. For routine questions, visit our pharmacy.
For general health information only. Always follow the latest official guidance and advice from healthcare professionals.
We are Ways Pharmacy in Holborn. Visit us for advice on inhaler technique and free blood pressure checks.
General health information only. Follow current official guidance and advice from healthcare professionals.
